Buy Piramal Pharma; target of Rs 171: Asit C Mehta
Asit C Mehta is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 171 in its research report dated April 01 2024.02-04-2024
02-04-2024
Trade Spotlight | How you should deal in RHI Magnesita India, Rainbow Childrens Medicare, Piramal Pharma today
Piramal Pharma has negated lower highs formation seen in previous 11 consecutive sessions and saw gap up opening on Tuesday. The stock formed bullish candlestick pattern with long upper shadow on the daily charts.20-03-2024
Stock Of The Day: Piramal Pharma May See Valuation Re-Rating, Says JefferiesAnalyst View, Key Levels
The brokerage maintained a 'buy' rating as it sees the stock's valuations as attractive when compared to its peers.19-03-2024
Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund18-03-2024
Piramal Pharma Ltd - 543635 - Intimation For Change In Domain Name Of The Website Of The Company
Intimation for change in domain name of the website of the Company13-03-2024
Piramal Pharma Ltd - 543635 - Intimation For Change In Domain Name Of The Website Of The Company
Intimation for change in domain name of the website of the Company.13-03-2024
Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG13-03-2024
Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201527-02-2024
Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG26-02-2024
Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
US-FDA Inspection at Piramal Pharma Limited''s Lexington Facility.24-02-2024